Tissue Regenix Group Plc (TRX) - Total Assets
Based on the latest financial reports, Tissue Regenix Group Plc (TRX) holds total assets worth GBX47.19 Million GBX (≈ $5.74K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Tissue Regenix Group Plc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Tissue Regenix Group Plc - Total Assets Trend (2007–2024)
This chart illustrates how Tissue Regenix Group Plc's total assets have evolved over time, based on quarterly financial data. Check TRX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Tissue Regenix Group Plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Tissue Regenix Group Plc's total assets of GBX47.19 Million consist of 46.9% current assets and 53.1% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 4.1% |
| Accounts Receivable | GBX4.38 Million | 9.7% |
| Inventory | GBX14.01 Million | 30.9% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX4.18 Million | 9.2% |
| Goodwill | GBX11.59 Million | 25.6% |
Asset Composition Trend (2007–2024)
This chart illustrates how Tissue Regenix Group Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TRX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tissue Regenix Group Plc's current assets represent 46.9% of total assets in 2024, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2024, up from 0.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 30.9% of total assets.
Tissue Regenix Group Plc Competitors by Total Assets
Key competitors of Tissue Regenix Group Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Tissue Regenix Group Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.88 | 3.74 | 5.48 |
| Quick Ratio | 0.77 | 1.47 | 4.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX14.88 Million | GBX15.34 Million | GBX19.02 Million |
Tissue Regenix Group Plc - Advanced Valuation Insights
This section examines the relationship between Tissue Regenix Group Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.24 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | GBX45.35 Million |
| Market Capitalization | $628.37 USD |
Valuation Analysis
Below Book Valuation: The market values Tissue Regenix Group Plc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tissue Regenix Group Plc's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tissue Regenix Group Plc (2007–2024)
The table below shows the annual total assets of Tissue Regenix Group Plc from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX45.35 Million ≈ $5.52K |
+4.86% |
| 2023-12-31 | GBX43.24 Million ≈ $5.26K |
+12.98% |
| 2022-12-31 | GBX38.27 Million ≈ $4.66K |
+12.15% |
| 2021-12-31 | GBX34.13 Million ≈ $4.15K |
-7.09% |
| 2020-12-31 | GBX36.73 Million ≈ $4.47K |
+20.45% |
| 2019-12-31 | GBX30.50 Million ≈ $3.71K |
-19.03% |
| 2018-12-31 | GBX37.66 Million ≈ $4.58K |
-17.70% |
| 2018-01-31 | GBX45.76 Million ≈ $5.57K |
0.00% |
| 2017-12-31 | GBX45.76 Million ≈ $5.57K |
+236.46% |
| 2016-12-31 | GBX13.60 Million ≈ $1.65K |
-58.83% |
| 2016-01-31 | GBX33.04 Million ≈ $4.02K |
+160.69% |
| 2015-01-31 | GBX12.67 Million ≈ $1.54K |
-61.74% |
| 2014-01-31 | GBX33.13 Million ≈ $4.03K |
-16.62% |
| 2013-01-31 | GBX39.73 Million ≈ $4.83K |
-11.32% |
| 2012-01-31 | GBX44.80 Million ≈ $5.45K |
+337.46% |
| 2011-01-31 | GBX10.24 Million ≈ $1.25K |
+175.46% |
| 2010-01-31 | GBX3.72 Million ≈ $452.33 |
+0.60% |
| 2009-01-31 | GBX3.70 Million ≈ $449.63 |
-62.17% |
| 2008-01-31 | GBX9.77 Million ≈ $1.19K |
+69.84% |
| 2007-01-31 | GBX5.75 Million ≈ $699.75 |
-- |
About Tissue Regenix Group Plc
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies for bone graft substitutes, skin, and soft tissue biologics markets in the United States and internationally. The company operates in two segments, dCELL and BioRinse. It offers dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal … Read more